You put a lot of effort into protecting patients from the flu. With Flucelvax® Quad, you can provide an exact antigenic matched vaccine to the WHO-selected influenza strains.1-4†

† Does not predict a clinical effect

DESIGNED TO BE AN EXACT MATCH TO WORLD HEALTH ORGANISATION (WHO) - SELECTED STRAINS 2,4-6 †

† Does not predict a clinical effect

Effectiveness

With clinical data in people 6 months and older, you have a new option for flu vaccination this season.1

Vaccine effectiveness of Flucelvax Quad versus egg-based influenza vaccines7-18

WATCH HOW OUR CELL-BASED TECHNOLOGY WORKS19

ESTABLISHED SAFETY PROFILE1,20-24

In clinical trials, the most commonly reported adverse events were mostly mild or moderate in intensity.1,20-24 These include:

  • pain/redness at the injection site
  • headache
  • fatigue
  • irritability (Children 6 months - 3 years)
  • adverse events were tolerated with a safety profile similar to other flu vaccines
  • in 2 large randomised controlled trials conducted in children (N=2,332) and adults (N=2,680) there were no serious adverse events assessed as being related to study vaccines
  • Flucelvax Quad is effective and well tolerated in pregnant women (Category A).27

†† Trivalent and quadrivalent doses

The importance of offering your patients a choice of influenza vaccine.

Brisbane GP, Dr Sarah Chu shares her experience on offering patients a choice of influenza vaccine and reflects on her clinical experience with Flucelvax® Quad.

Summary

Important information regarding ordering Flucelvax Quad for 2024

Flucelvax Quad will be available unfunded for the 2024 influenza season

Flucelvax Quad can be ordered directly from HCL in the usual manner. Note: no minimum order quantity and no small order charge apply.

In 2024 Flucelvax Quad (pre-filled syringe with attached needle) will cost $17.00+GST per dose from HCL, and will be available in boxes of 10 units.

References: 1. Flucelvax Quad Data sheet June 2024. 2. Centers for Disease Control and Prevention. Cell-based flu vaccines. Accessed Dec 2024. https://www.cdc.gov/flu/prevent/cell-based.htm 3. Rockman S et al. Vaccines (Basel). 2022;11(1):52. doi:10.3390/vaccines11010052 . 4. Rajaram S et al. Ther Adv Vaccines Immunother. 2020;8:2515135520908121. doi:10.1177/2515135520908121 5. Mabrouk T et al. Dev Biol (Basel). 2002;110:125–134. 6. WHO. Influenza A(H3N2) lineage cell culture-derived CVVs for development and production of vaccines for use in the 2022 SH influenza season; Available from: https://cdn.who.int/ media/docs/default-source/influenza/cvvs/cvv-southern-hemisphere-2022/ a(h3n2)---cell-culture-derived.pdf-cell_sh21.pdf?ua=1 Accessed Dec 2024. 7. Stein AN, et al. Open Forum Infect Dis. 2024;11(5):ofae175. 8. Stein AN et al Abstract presented OPTIONS 2024, September. 9. Divino V, et al. Vaccine.2020;38:6334-6343. 10. Krishnarajah G, et al. Vaccines (Basel). 2021;9(2):80. 11. Divino V, et al. Open Forum Infect Dis. 2021;9(1):ofab604. 12. Boikos C, et al. Clin Infect Dis.2020;71(10):e665-e671.13. Boikos C, et al. Vaccines (Basel). 2022;10(6):896 13. Eick-Cost et al. International Conference on Emerging Diseases 2018. P109. 14. Bruxvoort KJ et al. Vaccine 37 (2019) 5807-5811. 15. DeMarcus L et al. Vaccine, 2019 (30): 4015-4021. 16. Martin ET et al. J Infect Dis, 2021; 223(12): 2062–2071. 17. Stein A et al. Presentation at ESWI Influenza Conference, 2023. 18 Tseng HF et al. Options X for the Control of Influenza 2019. Abstract 10395. 19. CSL Seqirus Data on File #11. 20. Bart S et al. Hum Vaccin Immunother. 2016;12(9):2278- 2288. 21. Hartvickson R et al. Int J Infect Dis. 2015;41:65-72. 22. FDA.http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM504789.pdf. Accessed Dec 2024. 23. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04074928. Accessed Dec 2024. 24. Essink BJ et al. Pediatrics. 2022. 150(5):e2022057509. 25. Seqirus Data on File #9. 26. Nolan T et al. N Engl J Med. 2021; 385:16; 27. Albano M et al. IDSOG. Virtual Poster. 2021; V130_11OB

Flucelvax® Quad is an unfunded Prescription Medicine. Flucelvax® Quad is an inactivated quadrivalent influenza vaccine, prepared in cell cultures as a suspension for injection, in a single-dose glass syringe. PRESENTATION: Each dose contains 60 micrograms/0.5 mL of surface haemagglutinin and neuraminidase from four influenza virus strains. INDICATIONS: For the prevention of influenza caused by Influenza Virus, types A and B, in adults and children 6 months of age and older. CONTRAINDICATIONS: Known severe allergic reaction (e.g. anaphylaxis) to a previous influenza vaccination or to any component of the vaccine. ADVERSE EVENTS: Local injection site pain, erythema and induration. Systemic headache, fatigue, myalgia, irritability, nausea, upper respiratory tract infection and nasopharyngitis. Post-marketing serious adverse events includes hypersensitivity reactions, anaphylactic shock; paraesthesia, Guillain-Barré syndrome; pruritus, urticaria, or non-specific rash; Extensive swelling of injected limb. PRECAUTIONS: Postpone immunisation in patients with febrile illness or acute infection. A protective immune response may not be elicited in all vaccine recipients, particularly in immunosuppressed patients. If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, the decision to give Flucelvax® Quad should be based on careful consideration of the potential benefits and risks. Treatment and supervision for anaphylactic reactions should be available. Co-administration with other vaccines has not been studied. DOSAGE AND ADMINISTRATION: By intramuscular injection only. Gently shake to produce a clear to slightly opalescent suspension before use. Store at 2–8°C; do not freeze; protect from light. Before prescribing, review the Flucelvax® Quad Data Sheet (June 2024) www.medsafe.govt.nz, Seqirus Auckland, 0800 502 757. Flucelvax® Quad is a registered trademark of Seqirus UK Ltd or its affiliates. Date of preparation: Dec 2024. NZ-FLU-24-0006. TAPS DA 2414ER. Updated December 2024. INSIGHT 13360